Cognitive screening · Primary care

Cognitive Screening in Primary Care: Add the Metabolic Picture

Cognitive screening in primary care should not stop at the score. A falling result in an insulin-resistant adult is a supply signal, and pairing it with metabolic and nutrient measurements lets the decline be interpreted rather than merely recorded.

A slipping cognitive score in an overweight patient is usually filed under early aging. The evidence supports reading it as a supply problem that can be measured before anyone calls it normal.

Cognitive screening in primary care usually stops at the score: pass, borderline, or refer. The patient who most needs a second look rarely triggers either path. He is in his late fifties, insulin resistant, carrying central weight, eating three meals a day plus snacks, and his result is a few points lower than it was three years ago. Chapter 1 of The Starved Brain, presented in the video Overfed and Starving, makes the case that this presentation is not an exception but the default, and that the decline is partly a materials problem hiding under an energy surplus.

Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It does not treat; it gives the ordering physician measurements that sit next to the cognitive result so the decline can be interpreted rather than merely recorded.

Is age-related brain atrophy really normal?

Radiology reports use normal age-related atrophy every day, and most of us have repeated it to patients. Dr. Padda counts himself among the clinicians who said it for years. The problem is the reference population. Pooling 56 longitudinal MRI studies of 2,211 healthy people, whole-brain loss begins near 0.2% a year at 35 and passes 0.5% a year after 60. Healthy there means without diagnosed disease; nobody in those cohorts was screened for insulin resistance or nutrient status. The curve we compare patients against is a curve of the unmeasured.

Bone went through the same relabeling. Density loss with age was once considered simply what happens to older women, until its dependence on vitamin D, calcium, protein and loading was established and it became osteoporosis, something clinicians screen for and manage. Brain volume has not had that conversation at scale.

What drives cognitive decline in an insulin-resistant patient?

The first is cerebral energy supply. In twelve cognitively normal APOE4 heterozygotes with a mean age of 30.7, regional glucose metabolism was 8.0–10.5% lower in Alzheimer-vulnerable cortex, with cognition unchanged. In 77 cognitively normal adults followed a mean 7.2 years, baseline hippocampal glucose metabolism predicted decline to Alzheimer’s disease with 81% accuracy, about 8 years ahead, though on only six converters. In 2,439 Framingham Offspring adults, fasting insulin tracked smaller total brain volume with diabetes excluded, while HbA1c did not.

The second is the methylation pathway. In 107 cognitively normal older adults scanned annually, the bottom tertile of plasma B12, below 308 pmol/L, carried an odds ratio of 6.17 for being in the fastest-losing tertile, with no one deficient by the 150 pmol/L cutoff. The gradient runs inside the reference range, which is precisely where a serum B12 is read as reassuring.

The third is structural and economic: a food supply that delivers cheap refined energy while displacing the densest sources of B12, choline and DHA, and a visit model that places cognition, weight and laboratory values in separate silos with separate owners. No single driver explains the slope. Together they describe the patient in the exam room.

The evidence tier, stated plainly

VITACOG randomized 271 adults over 70 with mild cognitive impairment to folic acid, B12 and B6 or placebo; annual atrophy measured 0.76% with the vitamins versus 1.08% with placebo, a 29.6% slowing, with the benefit concentrated above a baseline homocysteine of 13.0 µmol/L and absent at or below 9.5. The Cochrane review of five trials in 879 people found probably little or no cognitive effect, called the atrophy finding a single study needing replication, and the trial leads hold patents on B vitamins for this use. Association is consistent across cohorts; the causal atrophy signal rests on one research group, and replication is the honest ask.

Those trials also enrolled almost no one with diabetes; the VITACOG imaging subgroup included fourteen. The overfed, insulin-resistant patient is missing from the evidence base, which is an argument for measuring him, not for waiting.

Who should get cognitive screening in primary care?

Metabolic dysfunction is the population baseline, not a niche. Metabolically healthy U.S. adults fell from under 12.2% on NHANES 2009–2016 to under 7% on the tighter post-2021 criteria. In the Padda clinic population the figure is under 3% overall and under 1% of chronic pain patients. Both clinic numbers come with a caveat: practice-reported figures from our own population, not trial outcomes, and individual results vary; even so, the direction is unmistakable. Reasonable triggers for pairing a cognitive assessment with metabolic measurement:

• Central adiposity, prediabetes or known insulin resistance with any downward change in a cognitive score.
• A report describing age-appropriate atrophy in a patient never screened metabolically.
• Long-term metformin use, which roughly doubles B12 deficiency risk (RR 2.09 across 31 studies).
• New falls, near-falls or balance complaints alongside memory or attention concerns.

The full criteria are in selection criteria.

What should a falling cognitive score change?

A cognitive result read alone produces a referral or a watchful wait. Paired, it changes the next order. Cognitive assessment establishes a scored baseline that later results are compared against. Laboratory panels frame the metabolic picture, and the ordering physician can extend them to B12 with methylmalonic acid or holotranscobalamin, homocysteine, fasting insulin as a number, 25-hydroxyvitamin D and the omega-3 index. Bioimpedance body composition separates fat mass from sarcopenic wasting, which BMI cannot. When cognition and gait slip together, vestibular and balance testing belongs in the same encounter, because a fall is often the first catastrophic event of a declining brain; the pairing is detailed in cognitive assessment and fall prevention.

The management decisions stay with the treating physician: repeat interval, nutrition and activity counseling, and whether a result warrants specialty referral. How each value is framed is covered in interpreting the report.

How does paired screening fit into a primary care workflow?

Pairing works only if it does not depend on someone remembering. Standing orders let staff initiate the protocol when a trigger is present, and making screening reproducible walks through how that is structured. The annual wellness visit already carries a look at cognition, so it is the natural anchor; see annual wellness visit integration. A documented baseline and follow-up also support MIPS and HEDIS reporting as quality and documentation work. The study-level evidence, including every limit named above, is in the Chapter 1 companion to The Starved Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and the patient-facing version of this argument is written for your patients. The Lancet Commission’s modifiable risks, turned into what a visit can actually measure, are in modifiable risk factors for dementia.

Frequently asked questions

Which patients benefit most from pairing cognitive and metabolic testing?

Adults with insulin resistance, prediabetes or central adiposity whose cognitive scores are drifting down, patients on long-term metformin, and anyone whose imaging report calls atrophy age-appropriate without a metabolic workup. Add balance concerns and the case strengthens. These patients were largely absent from the trials, so measurement is the only way to characterize them. See clinical rationale.

Does a serum B12 inside the reference range rule out a contribution to atrophy?

No. In 107 cognitively normal older adults, the fastest brain-volume losers clustered in the bottom tertile of B12, below 308 pmol/L, and none were deficient by the 150 pmol/L cutoff. Functional markers such as methylmalonic acid or holotranscobalamin, plus homocysteine, give a more useful read than serum B12 alone. How to order those functional markers in practice is covered in screening beyond serum B12.

How strong is the evidence that correcting B-vitamin status slows atrophy?

Moderate for association, thin for causation. One randomized trial found atrophy 29.6% slower on B vitamins, strongest when homocysteine was above 13.0 µmol/L, while a Cochrane review of five trials found probably little cognitive effect. The work comes largely from one patent-holding group. The practice position is to measure and treat the individual. Why timing decides whether B vitamins help is set out in B vitamins in mild cognitive impairment.

Where does this fit in an existing visit structure?

The annual wellness visit is the obvious anchor because cognition is already reviewed there. Standing orders can route patients who meet selection triggers into metabolic, body-composition and balance measurement without a separate decision each time, and results return to the ordering physician for management. See staffing and workflow.

Why add balance testing to a cognitive workup?

Declining cognition and declining balance travel together, and a fall can turn a slow decline into an abrupt loss of independence. Measuring both in one encounter gives the physician a fuller risk picture and a clearer reason to act on the metabolic findings. See vestibular and balance testing for what the test measures.

References

• Hedman, A. M., van Haren, N. E. M., Schnack, H. G., Kahn, R. S., & Hulshoff Pol, H. E. (2012). Human brain changes across the life span: A review of 56 longitudinal magnetic resonance imaging studies. Human Brain Mapping, 33(8), 1987–2002. https://doi.org/10.1002/hbm.21334
• Mosconi, L., De Santi, S., Li, J., Tsui, W. H., Li, Y., Boppana, M., Laska, E., Rusinek, H., & de Leon, M. J. (2008). Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiology of Aging, 29(5), 676–692. https://doi.org/10.1016/j.neurobiolaging.2006.12.008
• Tan, Z. S., Beiser, A. S., Fox, C. S., Au, R., Himali, J. J., Debette, S., DeCarli, C., Vasan, R. S., Wolf, P. A., & Seshadri, S. (2011). Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: The Framingham Offspring Study. Diabetes Care, 34(8), 1766–1770. https://doi.org/10.2337/dc11-0308
• Vogiatzoglou, A., Refsum, H., Johnston, C., Smith, S. M., Bradley, K. M., de Jager, C., Budge, M. M., & Smith, A. D. (2008). Vitamin B12 status and rate of brain volume loss in community-dwelling elderly. Neurology, 71(11), 826–832. https://doi.org/10.1212/01.wnl.0000325581.26991.f2
• Smith, A. D., Smith, S. M., de Jager, C. A., Whitbread, P., Johnston, C., Agacinski, G., Oulhaj, A., Bradley, K. M., Jacoby, R., & Refsum, H. (2010). Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS ONE, 5(9), e12244. https://doi.org/10.1371/journal.pone.0012244
• McCleery, J., Abraham, R. P., Denton, D. A., Rutjes, A. W. S., Chong, L.-Y., Al-Assaf, A. S., Griffith, D. J., Rafeeq, S., Yaman, H., Malik, M. A., Di Nisio, M., Martínez, G., Vernooij, R. W. M., & Tabet, N. (2018). Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment. Cochrane Database of Systematic Reviews, 2018(11), CD011905. https://doi.org/10.1002/14651858.CD011905.pub2
• Yang, W., Cai, X., Wu, H., & Ji, L. (2019). Associations between metformin use and vitamin B12 levels, anemia, and neuropathy in patients with diabetes: A meta-analysis. Journal of Diabetes, 11(9), 729–743. https://doi.org/10.1111/1753-0407.12900
• Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004). Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proceedings of the National Academy of Sciences of the United States of America, 101(1), 284–289. https://doi.org/10.1073/pnas.2635903100

Related reading

• Fasting Insulin Screening: The Gate on the Brain’s Second Fuel
• Cognitive Assessment

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.